284 related articles for article (PubMed ID: 22565480)
1. The pharmacological properties and therapeutic use of apomorphine.
Ribarič S
Molecules; 2012 May; 17(5):5289-309. PubMed ID: 22565480
[TBL] [Abstract][Full Text] [Related]
2. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation.
Himeno E; Ohyagi Y; Ma L; Nakamura N; Miyoshi K; Sakae N; Motomura K; Soejima N; Yamasaki R; Hashimoto T; Tabira T; LaFerla FM; Kira J
Ann Neurol; 2011 Feb; 69(2):248-56. PubMed ID: 21387370
[TBL] [Abstract][Full Text] [Related]
4. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
5. [A drug targeting intracellular amyloid-β and oxidative stress: apomorphine].
Ohyagi Y
Rinsho Shinkeigaku; 2011 Nov; 51(11):884-7. PubMed ID: 22277403
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine does not influence olfactory thresholds in Parkinson's disease.
Roth J; Radil T; Růzicka E; Jech R; Tichý J
Funct Neurol; 1998; 13(2):99-103. PubMed ID: 9626594
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine (TAP holdings). 6a beta-aporphine-10,11-diol hydrochloride hemihydrate, apomorphine hydrochloride, spontane, Uprima.
Drugs R D; 1999 Dec; 2(6):415-6. PubMed ID: 10763454
[No Abstract] [Full Text] [Related]
8. Clinical usefulness of apomorphine in movement disorders.
Colosimo C; Merello M; Albanese A
Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
[TBL] [Abstract][Full Text] [Related]
9. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and therapeutic value of apomorphine in Parkinsonian patients.
Sharma JC; Macnamara L; Hasoon M; Vassallo M
Int J Clin Pract; 2004 Nov; 58(11):1028-32. PubMed ID: 15605666
[TBL] [Abstract][Full Text] [Related]
11. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine-induced penile erections in Parkinson's disease.
O'Sullivan JD; Hughes AJ
Mov Disord; 1998 May; 13(3):536-9. PubMed ID: 9613749
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
Papuć E; Trzciniecka O; Rejdak K
Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
[TBL] [Abstract][Full Text] [Related]
14. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.
Sesar Á; Fernández-Pajarín G; Ares B; Rivas MT; Castro A
J Neurol; 2017 May; 264(5):946-954. PubMed ID: 28364292
[TBL] [Abstract][Full Text] [Related]
16. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease.
Luthra PM; Kumar JB
Mini Rev Med Chem; 2012 Dec; 12(14):1556-64. PubMed ID: 22697513
[TBL] [Abstract][Full Text] [Related]
17. Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.
Sesar Á; Fernández-Pajarín G; Ares B; Relova JL; Arán E; Rivas MT; Gelabert-González M; Castro A
J Neurol; 2019 Mar; 266(3):659-666. PubMed ID: 30617907
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction.
Montorsi F; Perani D; Anchisi D; Salonia A; Scifo P; Rigiroli P; Zanoni M; Heaton JP; Rigatti P; Fazio F
Int J Impot Res; 2003 Jun; 15(3):203-9. PubMed ID: 12904807
[TBL] [Abstract][Full Text] [Related]
20. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
Monti JM; Jantos H
Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
